{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
phenyl aminosalicylate
to a specific field?
Status:
Investigational
Source:
NCT00316797: Phase 1 Interventional Completed Neurodegenerative Diseases
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04454658: Phase 1 Interventional Active, not recruiting Myelofibrosis (MF)
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:trotabresib [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:irucalantide [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
USAN:UZOPTIRINE [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03851640: Phase 3 Interventional Recruiting MCRPC
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01401504: Phase 1 Interventional Completed Solid Tumor
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
ASP-3026 is a ALK tyrosine kinase receptor inhibitor which was developed by Astellas Pharma for the treatment of cancer conditions. The drug is being tested in phase I of clinical trials in patients with solid tumors, B-cell lymphoma and non-small cell lung carcinoma. The drug was discontinued for strategic reasons.
Status:
Investigational
Source:
INN:zanzalintinib [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03850574: Phase 1/Phase 2 Interventional Recruiting Leukemia, Myeloid, Acute
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03591094: Phase 2 Interventional Completed Cystic Fibrosis
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
